Outlook Therapeutics Taps Retina Veteran DiPasquale as CCO Ahead of LYTENAVA Launch
Event summary
- Greg DiPasquale named Chief Commercial Officer of Outlook Therapeutics, effective October 2026
- DiPasquale previously led commercial teams at Novartis, Regeneron, and Harrow, with five retina product launches
- LYTENAVA, the first FDA-approved ophthalmic formulation of bevacizumab for wet AMD, set for U.S. launch by year-end 2026
- DiPasquale will oversee market access, commercial operations, marketing, sales, and reimbursement teams
- LYTENAVA already approved in Europe, awaiting pricing and reimbursement approval in certain EU member states
The big picture
Outlook Therapeutics is positioning itself for a competitive entry into the wet AMD market with LYTENAVA, leveraging DiPasquale's deep retina commercialization experience. The appointment comes as the company prepares for its first major U.S. product launch, following regulatory approvals in both the U.S. and Europe. Success will depend on overcoming established competitors and navigating complex reimbursement landscapes.
What we're watching
- Commercial Execution
- Whether DiPasquale can translate his retina launch experience into rapid LYTENAVA adoption
- Market Penetration
- The pace at which LYTENAVA gains share against established wet AMD treatments
- Regulatory Hurdles
- How quickly Outlook secures pricing and reimbursement approvals in key European markets
